Invesco QQQ, ProShares UltraPro Short QQQ, Rocket Lab, CoreWeave, Ondas, Rapt Therapeutics, and AST SpaceMobile are the seven Value stocks to watch today, according to MarketBeat's stock screener...
MarketBeat·2h ago
More News
Promising Small Cap Stocks To Watch Today - January 20th
Rapt Therapeutics, Corvus Pharmaceuticals, INVO Fertility, Spring Valley Acquisition, Critical Metals, Inflection Point Acquisition, and Direxion Daily MU Bull 2X Shares are the seven Small Cap...
MarketBeat·2h ago
Lifesci Capital Reaffirms "Market Perform" Rating for Rapt Therapeutics (NASDAQ:RAPT)
Lifesci Capital reiterated a "market perform" rating on shares of Rapt Therapeutics in a research note on Tuesday...
MarketBeat·2h ago
Rapt Therapeutics (NASDAQ:RAPT) Earns "Equal Weight" Rating from Wells Fargo & Company
Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $58.00 target price on shares of Rapt Therapeutics in a research report on Tuesday...
MarketBeat·2h ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT...
PR Newswire·3h ago
Promising Medical Stocks To Follow Today - January 20th
Rapt Therapeutics, Johnson & Johnson, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded...
MarketBeat·3h ago
Top Pharmaceutical Stocks To Follow Now - January 20th
Rapt Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Corvus Pharmaceuticals, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...
MarketBeat·3h ago
Rapt Therapeutics' (RAPT) "Hold" Rating Reaffirmed at TD Cowen
TD Cowen reiterated a "hold" rating on shares of Rapt Therapeutics in a report on Tuesday...
MarketBeat·4h ago
HC Wainwright Reaffirms "Neutral" Rating for Rapt Therapeutics (NASDAQ:RAPT)
HC Wainwright restated a "neutral" rating and set a $58.00 price objective on shares of Rapt Therapeutics in a report on Tuesday...
MarketBeat·4h ago
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 1-Year High - Still a Buy?
Rapt Therapeutics (NASDAQ:RAPT) Hits New 52-Week High - Still a Buy...